1742. Kinetics of CMV Viremia with Letermovir Prophylaxis in the First 100 Days post Hematopoietic Cell Transplantation (HCT): A Single-center Experience

BACKGROUND: Letermovir (LTV) is approved for the prevention of CMV infection in CMV seropositive (R+) HCT recipients. Low rates of CMV breakthrough viremia have been reported with LTV prophylaxis. We studied the kinetics of CMV reactivation up to day (D) +100 in patients (patients) receiving LTV pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zavras, Phaedon D, Stern, Anat, Su, Yiqi, Fang, Jiaqi, Giralt, Sergio, Perales, Miguel, Maloy, Molly, Seo, Susan K, Papanicolaou, Genovefa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809059/
http://dx.doi.org/10.1093/ofid/ofz360.1605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809059/
http://dx.doi.org/10.1093/ofid/ofz360.1605

Ejemplares similares